Neurocognitive deficits associated with the hepatitis C virus among incarcerated men

Hepatitis C virus as a systemic disease: reaching beyond the liver

Chronic hepatitis C (CHC) is associated with multiple extrahepatic manifestations that may impact infected patients. The mechanisms through which these develop include those which are immunological, in which the chronic persistence of virus leads to the circulation of immune complexes (mixed cryoglobulinemia) and other autoimmune phenomena, and those which are virological and related to the extrahepatic tropism of the virus to other tissues. It is estimated that 40-74 % of patients with CHC may develop at least one extrahepatic manifestation during the course of the disease. Extrahepatic syndromes may represent the first signal of hepatitis C infection in some patients. CHC is associated with a four-fold increased risk of insulin resistance and type 2 diabetes mellitus; with cardiovascular disease in 17-37 % of patients; and with increased risk for cerebrovascular deaths, with a biological gradient of cerebrovascular mortality correlating with an increasing serum viral load. CHC is also associated with lymphoproliferative disorders, particularly non-Hodgkin B-cell lymphoma. The kidney is involved in 35-60 % of patients with CHC-associated mixed cryoglobulinemia. The prevalent type of glomerulonephritis associated with mixed cryoglobulinemia is membranoproliferative glomerulonephritis. In 30 % of cases, renal involvement begins with a nephritis syndrome and acute renal failure, while in 55 % there is only mild hematuria, microalbuminuria, proteinuria and renal insufficiency. CHC is also associated with cognitive impairment, especially in memory and concentration. Thus, extrahepatic CHC manifestations involve multiple organ systems outside the liver linked to a variety of comorbidities which may lead to significantly increased mortality from non-liver-related events.

Evaluating Neurocognitive Deficits in Patients With Multiple Sclerosis Via a Brief Neuropsychological Approach

Recent research demonstrates neurocognitive deficits are present early in the sequelae of multiple sclerosis (MS). This is an important consideration given the functional activities of daily living, such as employment, that can be impacted by neurocognitive dysfunction. This study investigated the utility of a brief neuropsychological battery, the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), to evaluate neurocognitive deficits in patients with MS and to examine the relationship between a measure of functional disability (Expanded Disability Status Scale [EDSS]) and the RBANS. Participants were 49 patients with MS (Mage = 45.39 years) who completed the RBANS as part of a neuropsychological assessment and 49 demographically matched healthy controls (Mage = 45.39 years). Multivariate analysis of variance revealed that the two groups differed on the RBANS. Descriptive discriminant analysis indicated the groups differed on domains of attention, language, immediate memory, and delayed memory. EDSS scores were a good predictor of neurocognitive dysfunction in patients with advanced disability but not for patients with mild disability. The RBANS seems to be effective in identifying cognitive dysfunction in patients with MS, and caution should be used in extrapolating cognitive deficits for patients with low EDSS scores.

Hepatitis C viral infection and the risk of dementia

BACKGROUND AND PURPOSE

Hepatitis C virus (HCV) infection may cause cognitive impairment, but no studies have focused specifically on cognitive impairment stemming from HCV. The purpose of this study was to investigate the potential increased risk for dementia in HCV-infected patients.

METHODS

A population-based cohort study based on the Taiwan National Health Insurance Research Database was conducted. From all potential participants aged 50 years or more, a total of 58,570 matched (1:1) pairs of HCV-infected patients and non-HCV-infected patients were included. Each subject was individually tracked from 1997 to 2009 to identify incident cases of dementia (onset in 1999 or later). Cox proportional hazards regressions were employed to calculate the hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between HCV infection and dementia.

RESULTS

There were 2989 dementia cases from the HCV-infected cohort during the follow-up period of 533,861.1 person-years; the overall incidence rates of dementia differed from the non-HCV cohort (56.0 vs. 47.7 cases per 10,000 person-years, P < 0.05). The adjusted HR for dementia was 1.36 (95% CI 1.27-1.42) for HCV-infected patients after adjusting for alcohol-related disease, liver cirrhosis, hepatic encephalopathy and hepatocellular carcinoma.

CONCLUSIONS

HCV infection may increase the risk for dementia. Further mechanistic research is needed.